Biocept Launches Liquid Biopsy Test for NRAS Mutations
"Our newest assay combines our proprietary switch blocker technology for improved mutation detection with the power of next generation sequencing, resulting in ultra-high sensitive performance of our liquid biopsy NRAS test," said
"We continue to execute on expanding our menu of non-invasive and cost-effective biomarker tests," said
About NRAS
The NRAS gene encodes for the N-Ras protein, which is involved in communicating signals from the exterior of the cell to the cell's interior (called signal transduction). These signals provide instructions for a cell to proliferate or differentiate. Mutations in the NRAS gene lead to dysregulated N-Ras protein function, resulting in uncontrolled cell growth and division. NRAS mutations are associated with the development of several types of cancer, such as melanoma (15-20% of cases), thyroid carcinoma (6%), colorectal cancer (1-6%), and lung cancer (1%). Currently, there are no
About NCCN Guidelines®
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research and education, is dedicated to improving the quality, effectiveness and efficiency of cancer care so that patients can live better lives. NCCN offers a number of programs to give clinicians access to tools and knowledge that can help guide decision-making in the management of cancer. Over the past 25 years, NCCN has developed an integrated suite of tools to improve the quality of cancer care. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment,
and supportive services that are most likely to lead to optimal outcomes.
About
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to identify specific
clinical conditions or improve the outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, the financial impact of new contracts, and our ability to increase the number of products or services provided or the value of the Company, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-launches-liquid-biopsy-test-for-nras-mutations-300511327.html
SOURCE
News Provided by Acquire Media